GM2-KLH vaccine

BIOLOGICAL2 trials

Sponsors

Memorial Sloan Kettering Cancer Center, European Organisation for Research and Treatment of Cancer - EORTC

Conditions

Breast CancerMelanoma (Skin)

Phase 1

Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease

CompletedNCT00003357

Memorial Sloan Kettering Cancer CenterBreast Cancer

Start: 1998-01-31End: 2001-11-30Target: 9Updated: 2012-12-13

Phase 3

Vaccine Therapy in Treating Patients With Primary Stage II Melanoma

European Organisation for Research and Treatment of Cancer - EORTCMelanoma (Skin)

Start: 1999-12-31Updated: 2009-02-09

Related Papers

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).

2011-05-18142 citations